Goh X, et al. - Researchers assessed the prevalence and clinico-pathological association of BRAF mutation in papillary thyroid cancer (PTC) patients. They included 75 consecutive histologically proven archival thyroid specimens from patients who had thyroidectomy for PTC. They noted 56% to be the prevalence of BRAF mutation in these patients. Findings suggested a link between BRAF-mutation-positive tumors and locally-advanced disease, but not poorer survival. BRAF mutation status and clinical outcomes were not significantly associated. The BRAFV600E mutation was seen in all but one BRAF-mutated PTC.